Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study-Reference-Cited by-同舟云学术

Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study

Published:2019-04-02 Issue:2 Volume:48 Page:250-255
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Smith Melanie N.^ORCID,Deloney Lindsay,Carter Cassandra,Weant Kyle A.,Eriksson Evert A.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11239-019-01846-5.pdf

Reference19 articles.

1. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS (2016) US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA 316(20):2115–2125. https://doi.org/10.1001/jama.2016.16201

2. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, ANNEXA-4 Investigators (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141. https://doi.org/10.1056/NEJMoa1607887

3. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr, ANNEXA-4 Investigators (2019) Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. https://doi.org/10.1056/nejmoa1814051

4. ANDEXXA [package insert] (2018) Portola Pharmaceuticals, Inc, South San Francisco

5. Grandhi R, Newman WC, Zhang X, Harrison G, Moran C, Okonkwo DO, Ducruet AF (2015) Administration of four-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg 84(6):1956–1961. https://doi.org/10.1016/j.wneu.2015.08.042

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor–associated major bleeds;Thrombosis Research;2024-08

2. Development of supramolecular anticoagulants with on-demand reversibility;Nature Biotechnology;2024-04-30

3. Management of DOAC-related bleeding in cancer patients: a single center-case series;Journal of Thrombosis and Thrombolysis;2024-03-31

4. The Effect of 4-Factor Prothrombin Complex Concentrate to Reverse Factor Xa Inhibitors in Patients With Traumatic Intracranial Hemorrhage;The American Surgeon™;2024-03-28

5. Ultra-Early Hemostatic Therapy for Acute Intracerebral Hemorrhage: An Updated Review;Cardiology in Review;2024-03-21